News

The criticality of venturing into new drugs has been discussed in the earlier segment, and an encouraging step has been taken in this direction. C4X Discovery (C4XD), a leading UK-based drug discovery company which develops new drug combinations for chronic addiction and cancer is credited to create its own VR tool named, 4Sight...

Clive Dix talks Proactive London's Andrew Scott through its interim results to January 2020.

Dix says its NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension is progressing and it is down to a short-list of three molecules.

29 April 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its interim results for the six months ended 31 January 2020.

Friday, 31 January 2020

Press Release Result of AGM

31 January 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that at its Annual General Meeting, held today at 11:00 am at Panmure Gordon & Co., One New Change, London EC4M 9AF, all resolutions were duly passed.

17 January 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that the Annual General Meeting of the Company will be held on 31 January 2020, at 11:00am, at Panmure Gordon, One New Change, London. The Annual Report and Financial Statements for the year ended 31 July 2019, has been published and sent to shareholders.

Dr Clive Dix, Chief Executive Officer, and members of the management team host this live presentation for analysts - watch this on-demand replay.

Tuesday, 07 January 2020

Press Release Full Year Results

7 January 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its full year results for the year ended 31 July 2019.

9 December 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to note the announcement that Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X3256) Under Fasting and Fed Conditions in Healthy Volunteers”.